Healthcare
West Pharmaceutical Services, Inc.(WST)
Live Price
Offline$328.80
-0.47% today
1Y Change
+51.73%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $21.21B
- Revenue Growth
- +6.3%
- EPS Growth
- +1.2%
- Dividend Yield
- 0.3%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
West Pharmaceutical Services, Inc. (WST) is a Healthcare stock with a market cap of $21.21B and listed on NYSE. The stock last traded around $328.80 and up 51.7% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +6.3%, EPS growth of +1.2%, a dividend yield of 0.3%. What stands out right now is revenue +6.3%, EPS +1.2%, free cash flow +69.6% with operating margin 20.7% and ROIC 15.2%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 39.8 and price/sales 6.6. Stock Foundry combines WST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.3% vs +7.6% peer median
Operating Margin
Near sector median
+20.7% vs +19.4% peer median
P/E
Above sector median
39.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.3% and EPS at +1.2%, with operating margin around 20.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | -1.1% | -3.9% | +2.1% |
2026 Feb 12, 2026 | +11.5% | +2.8% | -1.0% | -3.3% |
2025 Oct 23, 2025 | +16.7% | -3.2% | -9.3% | -16.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WST
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
WST Max Drawdown
-24.83%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WST and SPY.
Company Overview
West Pharmaceutical Services, Inc.
New York Stock Exchange
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
- Leadership
- Eric Green
- IPO Date
- Mar 17, 1980
- Employees
- 10.6k
- Street Address
- 530 Herman O. West Drive
- Mailing
- Exton, PA, 19341-0645
- Region
- Exton, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 594 2900
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 39.8
- EV/EBITDA
- 26.3
- Price/Sales
- 6.6
- Price/Book
- 7.2
Growth
- Revenue
- +6.3%
- EPS
- +1.2%
- Free Cash Flow
- +69.6%
Profitability
- Gross Margin
- 36.2%
- Operating Margin
- 20.7%
- Net Margin
- 16.9%
- ROE
- 17.9%
- ROIC
- 15.2%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 2.71
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.